Dutch take the lead on biosimilar switching - others to follow?
This article was originally published in Scrip
As evidence accumulates on the use of biosimilars in the real-world setting, it looks as if regulatory agencies in Europe may be softening their stance on interchangeability after the Dutch regulator the MEB came out in favour of allowing patients taking one biotherapeutic product to be switched to another, including a biosimilar.
You may also be interested in...
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.